Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Can Fite BiopharmaCANF -6.47%60 Cash-to-Debt is 120.28 as of Dec. 2025, which is 15% below its 10-year median of 141.48. GuruFocus rates CANF with a GF Score™ of 60/100 and a GF Value™ of $5.72 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,393 Biotechnology companies, Can Fite Biopharma ranks better than 77.46% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Can Fite Biopharma's cash to debt ratio for the quarter that ended in Dec. 2025 was 120.28.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Can Fite Biopharmacould pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Can Fite Biopharma's Cash-to-Debt or its related term are showing as below:
CANF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 36.79 Med: 141.48 Max: No Debt
Current: 120.19
During the past 13 years, Can Fite Biopharma's highest Cash to Debt Ratio was No Debt. The lowest was 36.79. And the median was 141.48.
CANF's Cash-to-Debt is ranked better than 77.46% of 1393
companies
in the Biotechnology industry
Industry Median: 6.78
vs CANF: 120.19
Can Fite Biopharma (AMEX:CANF) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Can Fite Biopharma Cash-to-Debt Related Terms
Can Fite Biopharma Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Can Fite Biopharma's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Can Fite Biopharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Can Fite Biopharma Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Can Fite Biopharma's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Can Fite Biopharma's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Can Fite Biopharma (CANF) has a Cash-to-Debt of 120.28 as of Dec. 2025. This is 15% below median its historical median of 141.48. Over the past decade, Can Fite Biopharma's Cash-to-Debt has ranged from 36.79 to 10,000.00. According to the industry distribution chart, Can Fite Biopharma ranks #314 out of 1393 companies in the Biotechnology industry, placing it in the top 22.5%.
Is Can Fite Biopharma's Cash-to-Debt too high?
Can Fite Biopharma's current Cash-to-Debt of 120.28 is 15% below median its 10-year median of 141.48. Over the past 10 years, this metric has ranged from a low of 36.79 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.78. Can Fite Biopharma's value of 120.28 is 1674% above this industry median. Based on the distribution chart, Can Fite Biopharma ranks #314 out of 1393 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Can Fite Biopharma has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Can Fite Biopharma's Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Can Fite Biopharma ranks #314 out of 1393 companies for Cash-to-Debt. This places Can Fite Biopharma in the top 23% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 6.78. Can Fite Biopharma's value of 120.28 is 1674% above this benchmark. Historically, Can Fite Biopharma's own Cash-to-Debt has ranged from 36.79 to 10,000.00 over the past decade. While the company's 10-year median is 141.48 vs. the industry median of 6.78, Can Fite Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.78, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Can Fite Biopharma's current Cash-to-Debt of 120.28 is 1674% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Can Fite Biopharma's current Cash-to-Debt is 120.28, which is 15% below median its own 10-year median of 141.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Can Fite Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Can Fite Biopharma (CANF) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.72, compared to a current price of $3.18 — trading 44.4% below its estimated fair value. The current Cash-to-Debt is 120.28, which is 15% below median its 10-year median of 141.48 and 1674% above the Biotechnology industry median of 6.78. Can Fite Biopharma's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Can Fite Biopharma (CANF), the current Cash-to-Debt is 120.28 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Can Fite Biopharma (CANF) Overvalued in 2026?
Based on GuruFocus' analysis, Can Fite Biopharma stock appears to be undervalued.
The current stock price of $3.18 is trading 44.4% below its estimated GF Value™ of $5.72.
GuruFocus considers Can Fite Biopharma to be Significantly Overvalued.
Key valuation signals for CANF:
Cash-to-Debt: 120.28 (15% below median its 10-year median of 141.48)
GF Value™: $5.72 vs. price of $3.18 (44.4% below fair value)
Industry Position: 1674% above the Biotechnology median (#314 of 1393)
No single metric tells the full story. See the CANF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
60GF Score
Get the complete analysis for CANF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CANF has been successfully added to your 
